Methotrexate in acute persistent humoral rejection: an option for graft rescue Fernando Bacal, MD, Gustavo L Sodré, MD, Daniela A Fernandes, MD, Vera D Aiello, MD, Noedir Stolf, MD, Edimar Bocchi, MD, Giovanni Bellotti, MD The Annals of Thoracic Surgery Volume 76, Issue 2, Pages 607-610 (August 2003) DOI: 10.1016/S0003-4975(03)00143-7
Fig 1 Immunofluorescence of myocardial tissue: (A) Focal positivity for immunoglobulin G in a small vessel (white arrow) (original magnification, ×400.) (B) Granular pattern of positivity for C3 in the interstitium (original magnification, ×400.) (C) Diffuse positivity for fibrinogen in the interstitium (original magnification, ×200). The Annals of Thoracic Surgery 2003 76, 607-610DOI: (10.1016/S0003-4975(03)00143-7)
Fig 2 Immunosuppression therapy used to treat the rejection in a patient with persistent cellular and humoral components. (ATGAM = polyclonal antibodies; FK506 =tacrolimus; MMF =mycophenolate mofetil; OKT3 = monoclonal antibodies; Rej = rejection.) The Annals of Thoracic Surgery 2003 76, 607-610DOI: (10.1016/S0003-4975(03)00143-7)